Navigation Links
Major Imaging Initiative to Shed Light on Little Known Brain Disease

UCSF scientists have received a $10 million grant from the National Institutes of Health to embark on a major neuroimaging study of a degenerative brain disease that is at least as common as Alzheimer’s disease in people under age 6

(Vocus) January 25, 2010 -- UCSF scientists have received a $10 million grant from the National Institutes of Health to embark on a major neuroimaging study of a degenerative brain disease that is at least as common as Alzheimer’s disease in people under age 60.

The fatal disease, known as frontotemporal dementia, affects decision-making, behavior, emotion and language. It gradually destroys the ability to behave in a socially appropriate manner, to empathize with others, learn, reason, make judgments, communicate and carry out daily activities. Because of the changes in personality that occur, the disease is perplexing for loved ones before a diagnosis is made and remains a particularly distressing disorder to manage. Some patients, as a result of their disease, mishandle money, commit adultery and carry out criminal behaviors, such as embezzlement.

Scientists have identified several mutated genes associated with the various forms of the disease, each of which in its own way leads to destruction of nerve cells in the frontal and temporal lobes of the brain. However, there are no therapies targeting the proteins the gene’s produce, though a multi-institutional trial is under way to test a drug that targets some of the disease’s symptoms.

The current study, led by Howard Rosen, MD, UCSF associate professor of neurology, is intended to determine how to use new imaging techniques to illuminate the changes that occur in the brain as the disease progresses. This information will enable scientists to identify biomarkers for diagnosis and, most importantly, track the impact of experimental drugs.

“Having accurate measures of the normal rates of change in FTD will be critical for planning future medication trials that will use imaging as an outcome,” says Rosen.

“While cognitive testing scores vary from day to day due to factors such as sleep quality and medication use, imaging studies measure brain structure and function precisely. They can reveal when a drug has slowed or reversed the brain shrinkage that would normally occur.”

UCSF and the Mayo Clinic in Rochester, Minnesota, will collaborate to enroll 120 FTD patients, as well as about 80 people who will serve as cognitively normal “controls.” Each participant will be followed for one and a half years with neurological examinations, cognitive and behavioral assessments, and brain imaging. Neurologist David Knopman, MD, will lead the Mayo team.

FTD is diagnosed by an assessment of a patient’s clinical history, and by neurological, cognitive and behavioral evaluations. Blood tests and neuroimaging supplement the process, but primarily help rule out other neurological disorders and provide additional evidence for FTD, rather than reveal a definitive diagnosis.

The new imaging project, which will begin in early 2010, will obtain several different types of images in each patient. Some will be obtained through structural magnetic resonance imaging, which measures the size and shape of the brain, and positron emission tomography, which examines aspects of metabolism, such as glucose consumption. Others will be obtained through promising new MRI techniques, including imaging to measure the blood content in the brain, and imaging to determine the integrity of the neural wiring, or axons, connecting various parts of the brain, using a technique called diffusion tensor imaging.

“It is possible that one or both of these techniques could replace PET scanning, which is expensive and requires exposure to radiation,” says Rosen. “This would lower the cost of clinical trials and make it possible for more patients to enroll because MRI scanners are commonly available.”

The study will investigate whether a combination of images, such as structural MRI, PET and DTI, will provide a better explanation of how a patient is doing than any one of these image types alone. It also will include serial assessments of the chemistry in the blood and cerebrospinal fluid the surrounds the brain, to see how these relate to changes in the brain images.

The new study, known as the Frontotemporal Lobar Degeneration Neuroimaging Initiative, takes advantage of the infrastructure developed for another major NIH-funded study of which UCSF is a leader, known as the Alzheimer’s Disease Neuroimaging Initiative, says Rosen.

The ADNI, begun in 2004, established procedures that make it possible to obtain comparable images at different centers, and has established procedures for ensuring high quality data. This year, the ADNI made a significant step forward in developing a test to help diagnose the beginning stages of Alzheimer’s disease sooner and more accurately by measuring levels of two biomarkers -- tau and beta-amyloid proteins -- in cerebrospinal fluid.

The FTLDNI is funded primarily by the National Institute of Aging, and is co-funded by the National Institute of Neurological Disease and Stroke.

Related links:

UCSF Memory and Aging Center – spotlight on FTD

UCSF Memory and Aging Center

Corinna Kaarlela, News Director
Source: Jennifer O’Brien (415) 476-2557


Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. The International Multiple Sclerosis Management Practice Announces Major Expansion Plans to NYC Headquarters
2. A Finnish-Swiss team cracks the atomic structure of a major cancer drug target
3. Sharing Miracles Features Major League Baseball Star Aaron Boone
4. American Lung Association Report Card: Federal Government Makes Major Strides; Most States Flunk for Neglecting to Prevent Tobacco-Caused Disease
5. Study identifies those elderly most at risk for major depression
6. Sharing Miracles Television Program to Feature Major League Baseball Star Aaron Boone
7. New Study Shows That American Public is Willing to Accept Major Reforms in Medicare Program
8. Former Senate Majority Leaders Baker, Daschle and Dole Commend Senate Passage of Health Care Bill
9. Mimotopes Awarded a Major Peptide Library Supply Agreement by La Jolla Institute for their Studies Screening Dengue and Tuberculosis Pathogens
10. Simone Announces Availability of Major Warehouse/Office Complex in the Bronx
11. New Commonwealth Fund survey of young adults finds wide majority support health reform
Post Your Comments:
(Date:11/24/2015)... , ... November 24, 2015 , ... In an ... restrictions and variables that determine which patients are or are not eligible for bariatric ... have a BMI over 40, are more than 100 pounds overweight, or have a ...
(Date:11/24/2015)... UT (PRWEB) , ... November 24, 2015 , ... It ... Magazine. For a business, it is critical that the first impression be positive and ... they are not likely to buy anything or want to return. They will also ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... gather to share their knowledge and experiences at a live taping of the ... Ruesch Center for the Cure of Gastrointestinal Cancers 2015 Symposium at Georgetown University ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Aided by ... today announced an innovative study designed to yield insights into how to detect and ... of biomarkers for pancreatic cancer from small, non-coding RNA molecules (ncRNA), genetic material that ...
(Date:11/24/2015)... ... November 24, 2015 , ... Sir Grout of Baltimore is ... certification. The award recognizes good companies for excellence in service and a commitment ... and hard surface restoration company earned this recognition after a thorough review by ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... November 24, 2015 F1000Workspace - ... - since it was launched just six months ago. ... and authoring platform for scientists - since it was launched ... have been loaded on to F1000Workspace - a ... since it was launched just six months ago. ...
(Date:11/24/2015)... YORK , Nov. 24, 2015 iRhythm Technologies, ... advancing cardiac care, today announced that it will participate in the ... Hotel in New York, NY . ... present on Tuesday December 1, 2015 at 8:50am ET. ... . --> . ...
(Date:11/24/2015)... uptake of recently approved and pipeline premium products for Type 1 Diabetes ... says GBI Research . --> The ... Mellitus (T1DM), will be a key driver of market growth to 2021, ... The uptake of recently approved and pipeline premium products for Type 1 ... 2021, says GBI Research . Type ...
Breaking Medicine Technology: